Mizuno Y, Kondo T
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Drug Saf. 1997 May;16(5):289-94. doi: 10.2165/00002018-199716050-00001.
A recent study by the Parkinson's Disease Research Group of the United Kingdom revealed higher mortality in patients with Parkinson's disease who were treated with selegiline (deprenyl) compared with those who were not. In this article, the methodological limitations of the UK study are discussed. Although several problems exist with this study, the mortality rate was correct, since the data were obtained from a verifiable source. The question then is whether or not the higher mortality rate can be ascribed to selegiline. It is difficult to find answers to this question in the study data, and we will have to wait for the study authors' final report. No other studies have reported higher mortality with selegiline. However, when prescribing selegiline in patients with early-stage Parkinson's disease, it is important to provide them with all the available information so that treatment decisions can be made jointly. Meanwhile, the best indication for selegiline appears to be motor fluctuations in patients with moderately advanced Parkinson's disease.
英国帕金森病研究小组最近的一项研究表明，与未接受司来吉兰（丙炔苯丙胺）治疗的帕金森病患者相比，接受该药物治疗的患者死亡率更高。在本文中，将讨论英国这项研究在方法上的局限性。尽管该研究存在若干问题，但死亡率数据是正确的，因为数据来源于可核实的出处。那么问题在于，较高的死亡率是否可归因于司来吉兰。在该研究数据中很难找到这个问题的答案，我们将不得不等待研究作者的最终报告。没有其他研究报告过司来吉兰会导致更高的死亡率。然而，在为早期帕金森病患者开司来吉兰处方时，向他们提供所有可用信息以便共同做出治疗决策非常重要。同时，司来吉兰的最佳适应证似乎是中度晚期帕金森病患者的运动波动。
